Anti cd11b apc cy7 clone m1 70

Manufactured by BD

Anti-CD11b-APC-Cy7 (clone M1/70) is a fluorescent-conjugated monoclonal antibody that binds to the CD11b cell surface antigen. CD11b is expressed on the surface of myeloid cells, including monocytes, macrophages, and neutrophils. The APC-Cy7 fluorescent dye is conjugated to the antibody, allowing for detection and analysis of CD11b-positive cells using flow cytometry.

Automatically generated - may contain errors

Lab products found in correlation

Anti cd45 percp clone 30 f11, by BD (1 mentions) Anti f4 80 apc clone bm8, by Thermo Fisher Scientific (1 mentions) Anti cd8 pacific blue clone 53 6.7, by BD (1 mentions) Lsrfortessa flow cytometer, by BD (1 mentions) Anti cd16 cd32, by Thermo Fisher Scientific (1 mentions) Fixable blue dead cell stain, by Thermo Fisher Scientific (1 mentions)

Close spelling variants of this product

CD11b (454 citations) Anti-CD11b (175 citations) APC-Cy7 (76 citations) CD11b-APC-Cy7 (75 citations) CD11b-APC (74 citations) CD11b (M1/70, (58 citations) CD11b (clone M1/70, (43 citations) M1/70 (41 citations) Anti-CD11b-APC (38 citations) Anti-CD11b (clone M1/70, (35 citations)

2 protocols using anti cd11b apc cy7 clone m1 70

Detailed Immune Cell Characterization in BALF

Check if the same lab product or an alternative is used in the 5 most similar protocols

BALF from infected mice were centrifuged (5 min, 5000×g) and one quarter of the cellular fraction was stained with anti-Gr1-FITC (clone RB6-8C5, eBioscience, 1:1000), anti-CD49b-PE (clone DX5, eBioscience, 1:1000), anti-CD45-PerCP (clone 30-F11, BD Biosciences, 1:300), anti-CD19-PE-Cy7 (clone 1D3, BD Biosciences, 1:2000), anti-F4/80-APC (clone BM8, eBioscience, 1:300), anti-CD11b-APC-Cy7 (clone M1/70, BD Biosciences, 1:300), anti-CD11c-Pacific-Blue (clone HL3, BD Biosciences, 1:300), and anti-CD3e-BV510 (clone 145-2C11, BD Biosciences, 1:100) for 20 min at 4°C. CD4 and CD8 T cells were stained in a second staining panel with anti-CD8-Pacific blue (clone 53–6.7, BD Biosciences, 1:300) and anti-CD4-PerCP (clone RM4-5, eBioscience, 1:2000).

Lapuente D., Stab V., Storcksdieck genannt Bonsmann M., Maaske A., Köster M., Xiao H., Ehrhardt C, & Tenbusch M. (2020). Innate signalling molecules as genetic adjuvants do not alter the efficacy of a DNA-based influenza A vaccine. PLoS ONE, 15(4), e0231138.

+ Open protocol

+ Expand

Flow Cytometry Analysis of Murine Lung Leukocytes

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Two million lung cells were incubated with 1.25 μg ml–1 anti-CD32/CD16 (eBioscience, San Diego, CA) in FACS wash buffer (PBS/2% FCS/0.1%) for 30 min to block Fc receptors, then washed and incubated for 30 min with anti-CD4-phycoerythrin (PE)-Cy7 (clone RM4–5, BD), anti-CD8a-Pacific Blue (clone 53–6.7, BD), anti-SiglecF-PE (clone E50–244, BD), anti-B220-allophycocyanin (APC) (clone RA3–6B2, BD), anti-CD11b-APCCy7 (clone M1/70, BD), anti-CD11c-BV785 (clone HL3, BD), anti-Ly6G-BV510 (clone 1A8, BD), anti-Ly6C-PerCPCy5.5 (clone AL-21, BD) and anti-NK1.1-fluorescein isothiocyanate (FITC) (clone PK136, BD). Fixable Blue Dead Cell Stain (Life Technologies) was added to allow dead cell discrimination. Cells were then fixed with formalin. All samples were acquired on a BD LSR-Fortessa flow cytometer (BD), and analysed using FlowJoTM analysis software (Treestar, Macintosh Version 9.8, Ashland, OR). The leukocyte gating strategy is described in [35 (link)].

Lin Y., Quan D., Chang R.Y., Chow M.Y., Wang Y., Li M., Morales S., Britton W.J., Kutter E., Li J, & Chan H.K. (2020). Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation—A proof-of-principle study in a P. aeruginosa lung infection model. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 158, 166-171.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!